Avalyn Pharma Inc. SEC filings AVLN

Avalyn Pharma Inc. has 63 filings in SEC EDGAR's recent list, going back to Nov 16, 2012. The latest quarterly report (Form 10-Q) was filed on Aug 12, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Sep 16, 2026 (officer or director change). The company's fiscal year ends on December 31.

Avalyn Pharma Inc. SEC filings
Form Description Filed Period
8-K Current report
Officer or director change
Sep 16, 2026 Sep 15, 2026
8-K Current report
Results of operations
Aug 12, 2026 Aug 12, 2026
8-K Current report
Material agreement
Jul 1, 2026 Jun 29, 2026
8-K Current report
Regulation FD disclosure
Jun 17, 2026 Jun 17, 2026
8-K Current report
Results of operations
Jun 3, 2026 Jun 3, 2026
8-K Current report
Bylaw or fiscal year change
May 1, 2026 May 1, 2026

Showing 6 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.

Company profile

Industry
Pharmaceutical Preparations (SIC 2834)
Listed as
AVLN (Nasdaq)
Fiscal year ends
December 31
Incorporated in
DE
Headquarters
Boston, MA
SEC filer status
, Emerging growth company
SEC CIK
1540171
Former names
Genoa Pharmaceuticals, Inc. (until May 24, 2017)

Other Pharmaceutical Preparations companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.